5-Amino-1MQ is sold and discussed alongside peptides, so it belongs in this
library — but it is important to begin with what it is not.
Chemical identity & structure.
5-Amino-1MQ (5-amino-1-methylquinolinium) is a **small molecule, not a
peptide.** It is a quinolinium compound. It is grouped with peptides only
because the research-compound market sells it that way; chemically it has
nothing in common with the peptides elsewhere in this library.
Mechanism of action.
5-Amino-1MQ is studied as an inhibitor of the enzyme nicotinamide
N-methyltransferase (NNMT). NNMT is involved in metabolic regulation in adipose
tissue and other tissues, and consumes a methyl group from a key cellular
cofactor. The research hypothesis is that inhibiting NNMT could shift cellular
metabolism in a way relevant to obesity and metabolic disease. This is a
hypothesis under investigation, not an established mechanism in humans.
Key research findings.
Preclinical research — primarily in rodents and cell models — has reported
effects on adipocyte metabolism, body weight, and metabolic markers when NNMT is
inhibited. The findings are interesting at the preclinical level.
The research / citation base.
The 5-Amino-1MQ literature is preclinical. There is essentially no
substantial human clinical-trial data, and the compound is not approved for
any use. Its human safety and efficacy profile is unknown. Marketing it as a
proven metabolic or weight-loss aid is far ahead of the evidence.
Research protocols in the literature.
Animal studies have used oral administration. There is no validated human
research protocol.
Quality & sourcing notes.
As a small molecule, identity and purity should still be documented on a
batch-specific COA (HPLC purity; identity confirmation by an appropriate method
for a small molecule rather than peptide mass spectrometry).
*Research-use note: Educational summary of published research. 5-Amino-1MQ is a
non-approved investigational compound described here for research context only;
nothing here is medical advice.*